Hawaii Biotech, Inc. will be receive a $261,990 grant to support the research and development of a vaccine for Crimean-Congo Hemorrhagic Fever (CCHF) Senator Daniel K. Inouye announced today.
The funding comes through a Small Business Innovation Research Grant administered by the U.S. Department of Health and Human Service's National Institute of Allergy and Infectious Diseases.
"Hawaii Biotech's important work researching and developing vaccines for infectious diseases is critical to the health of our communities," said Senator Inouye. "Hawaii's geographic isolation and its popularity as a tourist destination make our state especially vulnerable to emerging infectious diseases. It is extremely important for our government to support the development of vaccines that ensure public safety by preventing the outbreak of lethal viruses."
For more information about Crimean-Congo Hemorrhagic Fever (CCHF), please visit:
For more information about Hawaii Biotech, Inc., please visit:
For more information about Small Business Innovation Research grants, please visit: